
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6821188/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Influence of endocrine multidisciplinary tumor board on patient management and treatment decision making. American Journal of Surgery, 2022, 223, 76-80.	1.8	4
2	Risk management recommendations and patient acceptance vary with high-risk breast lesions. American Journal of Surgery, 2022, 223, 94-100.	1.8	3
3	Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer. Surgery, 2022, 171, 245-251.	1.9	3
4	Blocking Gi/o-Coupled Signaling Eradicates Cancer Stem Cells and Sensitizes Breast Tumors to HER2-Targeted Therapies to Inhibit Tumor Relapse. Cancers, 2022, 14, 1719.	3.7	2
5	The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer. Surgery, 2022, 171, 657-665.	1.9	6
6	Racial disparities in comorbid conditions among patients undergoing thyroidectomy for Graves' disease: An ACS-NSQIP analysis. American Journal of Surgery, 2021, 221, 106-110.	1.8	7
7	AP-2Î <sup>3</sup> Is Required for Maintenance of Multipotent Mammary Stem Cells. Stem Cell Reports, 2021, 16, 106-119.	4.8	4
8	AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer. Molecular Cancer Research, 2021, 19, 1156-1167.	3.4	11
9	A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 456-462.	1.3	6
10	AP-2α–Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis. Cancer Research, 2021, 81, 4455-4470.	0.9	15
11	Targeting Gi/o protein–coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy. JCI Insight, 2021, 6, .	5.0	13
12	Unanticipated Admission Following Outpatient Laparoscopic Cholecystectomy: Identifying Opportunities for Improvement. American Surgeon, 2021, 87, 1080-1086.	0.8	1
13	A <i>TFAP2C</i> Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer. Molecular Cancer Research, 2020, 18, 46-56.	3.4	15
14	Illuminated Transhiatal Retractor for Mediastinal Dissection During Transhiatal Esophagectomy. Annals of Thoracic Surgery, 2020, 109, e67-e69.	1.3	1
15	TFAP2C regulates carbonic anhydrase XII in human breast cancer. Oncogene, 2020, 39, 1290-1301.	5.9	16
16	Academic Advancement in Global Surgery: Appointment, Promotion, and Tenure. Annals of Surgery, 2020, 271, 279-282.	4.2	7
17	The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database. Journal of Gastrointestinal Surgery, 2020, 24, 1402-1410.	1.7	19
18	Cancer cell-intrinsic function of CD177 in attenuating β-catenin signaling. Oncogene, 2020, 39, 2877-2889.	5.9	11

#	Article	IF	CITATIONS
19	Randomized Trial of Perioperative Probiotics Among Patients Undergoing Major Abdominal Operation. Journal of the American College of Surgeons, 2019, 229, 533-540e1.	0.5	11
20	Timing of Esophagectomy after Neoadjuvant Chemoradiation Therapy Affects the Incidence of Anastomotic Leaks. Korean Journal of Thoracic and Cardiovascular Surgery, 2019, 52, 1-8.	0.6	11
21	Discordant findings on preoperative imaging for primary hyperparathyroidism and thyroid disease: Choosing the path to follow. Surgery, 2019, 166, 678-685.	1.9	2
22	The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2019, 23, 1957-1963.	1.7	23
23	Poorly differentiated neuroendocrine carcinoma of the breast with Merkel cell features. Breast Journal, 2018, 24, 644-647.	1.0	6
24	Nipple-Sparing Mastectomy is Not Associated with a Delay of Adjuvant Treatment. Annals of Surgical Oncology, 2018, 25, 1928-1935.	1.5	10
25	Per oral endoscopic myotomy: early experience and safety of a multispecialty approach. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 3357-3363.	2.4	7
26	Intraoperative Radiotherapy for Breast Cancer Treatment in a Rural Community. Annals of Surgical Oncology, 2018, 25, 3004-3010.	1.5	6
27	Risk factors for 30-day readmission after adrenalectomy. Surgery, 2018, 164, 766-773.	1.9	14
28	Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013. American Journal of Surgery, 2017, 214, 323-328.	1.8	8
29	Comparative analysis of radioactive iodine versus thyroidectomy for definitive treatment of Graves disease. Surgery, 2017, 161, 147-155.	1.9	21
30	Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer. Oncotarget, 2017, 8, 114801-114815.	1.8	12
31	Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. Stem Cell Reports, 2016, 7, 1140-1151.	4.8	47
32	Key Tenets of Effective Surgery Leadership. JAMA Surgery, 2016, 151, 768.	4.3	19
33	EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib. Molecular Cancer Therapeutics, 2016, 15, 503-511.	4.1	31
34	Presidential Forum Discussion. Annals of Surgery, 2015, 262, 555-562.	4.2	0
35	Surgical Management of Breast Cancer in 2010–2011 SEER Registries by Hormone and HER2 Receptor Status. Annals of Surgical Oncology, 2015, 22, 566-572.	1.5	17
36	Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. Annals of Surgical Oncology, 2015, 22, 4287-4294.	1.5	21

RONALD J WEIGEL

#	Article	IF	CITATIONS
37	Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells. Cancer Research, 2015, 75, 1972-1982.	0.9	53
38	2015 Presidential Address—Society of Surgical Oncology: The Next 75 Years. Annals of Surgical Oncology, 2015, 22, 2455-2461.	1.5	2
39	Regulation of Epithelial–Mesenchymal Transition through SUMOylation of Transcription Factors. Cancer Research, 2015, 75, 11-15.	0.9	62
40	A Novel Animal Model for Locally Advanced Breast Cancer. Annals of Surgical Oncology, 2015, 22, 866-873.	1.5	13
41	Laparoscopic Drainage of Retroperitoneal Hematoma. CRSLS MIS Case Reports From SLS, 2015, 19, .	0.2	Ο
42	Targeting the sumoylation pathway in cancer stem cells. Molecular and Cellular Oncology, 2014, 1, e964624.	0.7	1
43	Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer. Clinical Cancer Research, 2014, 20, 2115-2125.	7.0	39
44	Sumoylation Pathway Is Required to Maintain the Basal Breast Cancer Subtype. Cancer Cell, 2014, 25, 748-761.	16.8	72
45	Rate of Contralateral Prophylactic Mastectomy is Influenced by Preoperative MRI Recommendations. Annals of Surgical Oncology, 2014, 21, 4133-4138.	1.5	13
46	Preoperative evaluation of thyroglossal duct cysts: children versus adults—is there a difference?. American Journal of Surgery, 2014, 207, 902-906.	1.8	3
47	Distinct Pathways Regulated by RET and Estrogen Receptor in Luminal Breast Cancer Demonstrate the Biological Basis for Combination Therapy. Annals of Surgery, 2014, 259, 793-799.	4.2	27
48	Training and certification of the surgical oncologist. Chinese Clinical Oncology, 2014, 3, 45.	1.2	15
49	The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. American Journal of Surgery, 2013, 206, 2-7.	1.8	45
50	Discriminating Pheochromocytomas from Other Adrenal Lesions: The Dilemma of Elevated Catecholamines. Annals of Surgical Oncology, 2013, 20, 3855-3861.	1.5	10
51	Review of risk factors for the development of contralateral breast cancer. American Journal of Surgery, 2013, 206, 704-708.	1.8	57
52	Do giant parathyroid adenomas represent a distinct clinical entity?. Surgery, 2013, 154, 714-719.	1.9	48
53	High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer. Journal of Surgical Research, 2013, 184, 519-525.	1.6	12
54	Expression of the RET Proto-oncogene Is Regulated by TFAP2C in Breast Cancer Independent of the Estrogen Receptor. Annals of Surgical Oncology, 2013, 20, 2204-2212.	1.5	24

#	Article	IF	CITATIONS
55	Management of Contralateral Axillary Sentinel Lymph Nodes Detected on Lymphoscintigraphy for Breast Cancer. Annals of Surgical Oncology, 2013, 20, 3317-3322.	1.5	22
56	Human Melanoma Cells Over-Express Extracellular Matrix 1 (ECM1) Which Is Regulated by TFAP2C. PLoS ONE, 2013, 8, e73953.	2.5	20
57	Effect of Introducing Hematoma Ultrasound-Guided Lumpectomy in a Surgical Practice. Journal of the American College of Surgeons, 2012, 215, 237-243.	0.5	13
58	Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt. Surgery, 2012, 152, 1218-1224.	1.9	8
59	Risk of Subsequent Primary Thyroid Cancer after Another Malignancy: Latency Trends in a Population-based Study. Annals of Surgical Oncology, 2012, 19, 1887-1896.	1.5	36
60	Management of Patients with Primary Hyperparathyroidism and Concurrent Thyroid Disease: An Evolving Field. Annals of Surgical Oncology, 2012, 19, 1428-1429.	1.5	10
61	Sampling of secondary margins decreases the need for re-excision after partial mastectomy. Surgery, 2011, 150, 802-809.	1.9	9
62	Surveillance and Intervention After Thyroid Lobectomy. Annals of Surgical Oncology, 2011, 18, 1729-1733.	1.5	21
63	Reply to Comment on "Surveillance and Intervention after Thyroid Lobectomyâ€. Annals of Surgical Oncology, 2011, 18, 309-309.	1.5	1
64	Management of pregnant women with breast cancer. Journal of Surgical Oncology, 2011, 103, 337-340.	1.7	31
65	Discovery of SMAD4 promoters, transcription factor binding sites and deletions in juvenile polyposis patients. Nucleic Acids Research, 2011, 39, 5369-5378.	14.5	15
66	Incidental Finding of Composite Pheochromocytoma-Ganglioneuroma: Successful Management after Emergent Appendectomy and Review of the Literature. World Journal of Endocrine Surgery, 2011, 3, 39-44.	0.0	2
67	Expansion of a Cell Population Expressing Stem Cell Markers in Parathyroid Glands From Patients With Hyperparathyroidism. Annals of Surgery, 2010, 251, 107-113.	4.2	11
68	Reply to, "RET Germline Mutations in Codon 609 and MEN2A Phenotype: Are They All Created Equal?―by Machens and Dralle (ASO-2009-06-0652). Annals of Surgical Oncology, 2010, 17, 333-333.	1.5	0
69	PET-CT scans in recurrent or persistent differentiated thyroid cancer: Is there added utility beyond conventional imaging?. Surgery, 2010, 148, 1082-1090.	1.9	11
70	Risk Factors for Development and Recurrence of Primary Breast Abscesses. Journal of the American College of Surgeons, 2010, 211, 41-48.	0.5	132
71	Reply: A Properly Performed Operation Almost Always Cures Chronic Subareolar Abscess and Fistula. Journal of the American College of Surgeons, 2010, 211, 693.	0.5	0
72	Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes and Cancer, 2010, 49, 948-962.	2.8	74

#	Article	IF	CITATIONS
73	Discovery of the BMPR1A promoter and germline mutations that cause juvenile polyposis. Human Molecular Genetics, 2010, 19, 4654-4662.	2.9	32
74	The use of touch preparation for the evaluation of sentinel lymph nodes in breast cancer. American Journal of Surgery, 2010, 199, 792-796.	1.8	13
75	The Biology of Breast Cancer. , 2010, , 83-96.		0
76	Interaction of TFAP2C with the Estrogen Receptor-α Promoter Is Controlled by Chromatin Structure. Clinical Cancer Research, 2009, 15, 3672-3679.	7.0	32
77	A single institutional experience of factors affecting successful identification of sentinel lymph node in breast cancer patients. Surgery, 2009, 146, 671-677.	1.9	23
78	Determinants of survival in patients with calciphylaxis: A multivariate analysis. Surgery, 2009, 146, 1028-1034.	1.9	69
79	Measurement of Uterine Radiation Exposure from Lymphoscintigraphy Indicates Safety of Sentinel Lymph Node Biopsy during Pregnancy. Annals of Surgical Oncology, 2009, 16, 1143-1147.	1.5	72
80	When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation?. Annals of Surgical Oncology, 2009, 16, 2237-2244.	1.5	20
81	Extracellular Matrix 1 (ECM1) Expression Is a Novel Prognostic Marker for Poor Long-Term Survival in Breast Cancer: A Hospital-Based Cohort Study in Iowa. Annals of Surgical Oncology, 2009, 16, 2280-2287.	1.5	45
82	GATA-3 as a Marker of Hormone Response in Breast Cancer. Journal of Surgical Research, 2009, 157, 290-295.	1.6	55
83	Physician Reimbursement for General Surgical Procedures in the Last Century: 1906â^2006. Journal of the American College of Surgeons, 2008, 206, 670-677.	0.5	19
84	Cancer of the Endocrine System. , 2008, , 1271-1305.		10
85	TFAP2C Controls Hormone Response in Breast Cancer Cells through Multiple Pathways of Estrogen Signaling. Cancer Research, 2007, 67, 8439-8443.	0.9	70
86	AP2 Transcription Factors Regulate Expression of CRABPII in Hormone Responsive Breast Carcinoma. Journal of Surgical Research, 2007, 138, 71-78.	1.6	28
87	The Role of Radioactive Iodine in the Treatment of Well-differentiated Thyroid Cancer. Surgical Oncology Clinics of North America, 2006, 15, 625-638.	1.5	10
88	Formation and Prevention of Postoperative Abdominal Adhesions. Journal of Surgical Research, 2006, 132, 3-12.	1.6	182
89	Surgeon-Performed Ultrasound for Preoperative Localization of Abnormal Parathyroid Clands in Patients with Primary Hyperparathyroidism. World Journal of Surgery, 2006, 30, 1658-1663.	1.6	38
90	Variability in the adoption of breast MRI among surgeons. Journal of Surgical Oncology, 2006, 93, 343-344.	1.7	0

RONALD J WEIGEL

#	Article	IF	CITATIONS
91	GATA-3 Expression as a Predictor of Hormone Response in Breast Cancer. Journal of the American College of Surgeons, 2005, 200, 705-710.	0.5	64
92	Effect of parathyroidectomy on polycythemia vera. Surgery, 2005, 137, 102-103.	1.9	2
93	Expression of ZER6 in ERα-Positive Breast Cancer. Journal of Surgical Research, 2005, 126, 86-91.	1.6	10
94	Physical and Functional Interactions between the Wwox Tumor Suppressor Protein and the AP-2Î <sup>3</sup> Transcription Factor. Cancer Research, 2004, 64, 8256-8261.	0.9	152
95	Incentive systems for academic productivity in a department of surgery1. Journal of the American College of Surgeons, 2004, 199, 300-307.	0.5	32
96	Utility of Very Delayed Parathyroid MIBI SPECT for Localization of Parathyroid Adenoma. Clinical Nuclear Medicine, 2004, 29, 727-729.	1.3	2
97	The journal of surgical research increases its science citation index: what's the impact?. Journal of Surgical Research, 2003, 114, 107-109.	1.6	3
98	Pituitary Tumor AP-2α Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4. Journal of Biological Chemistry, 2003, 278, 19597-19602.	3.4	45
99	Common and Uncommon Sonographic Features of Papillary Thyroid Carcinoma. Journal of Ultrasound in Medicine, 2003, 22, 1083-1090.	1.7	274
100	Tumor Suppressor Activity of AP2α Mediated through a Direct Interaction with p53. Journal of Biological Chemistry, 2002, 277, 45028-45033.	3.4	84
101	A Novel Zinc Finger Transcription Factor with Two Isoforms That Are Differentially Repressed by Estrogen Receptor-α. Journal of Biological Chemistry, 2002, 277, 9326-9334.	3.4	25
102	Sonography in Primary Hyperparathyroidism. Journal of Ultrasound in Medicine, 2002, 21, 539-552.	1.7	90
103	Needle Track Seeding of Papillary Thyroid Carcinoma from Fine Needle Aspiration Biopsy. Acta Cytologica, 2002, 46, 591-595.	1.3	57
104	Intraoperative ultrasonography improves identification of recurrent thyroid cancer. Surgery, 2002, 132, 924-929.	1.9	65
105	Intraoperative ultrasonography for localization of recurrent thyroid cancer. Surgery, 2001, 129, 498-500.	1.9	7
106	Recombinant human thyrotropin in the management of thyroid cancer. Current Opinion in Oncology, 2001, 13, 39-43.	2.4	39
107	Nonoperative management of hyperparathyroidism: present and future. Current Opinion in Oncology, 2001, 13, 33-38.	2.4	19
108	Genetic Analysis of a Papillary Thyroid Carcinoma in a Patient with MEN1. Annals of Surgical Oncology, 2001, 8, 342-346.	1.5	15

RONALD J WEIGEL

#	Article	IF	CITATIONS
109	Ligand-dependent Interaction of Estrogen Receptor-α with Members of the Forkhead Transcription Factor Family. Journal of Biological Chemistry, 2001, 276, 33554-33560.	3.4	137
110	Genomic Structure of the Promoters of the Human Estrogen Receptor-α Gene Demonstrate Changes in Chromatin Structure Induced by AP2γ. Journal of Biological Chemistry, 2001, 276, 15519-15526.	3.4	34
111	Genetic Analysis of a Papillary Thyroid Carcinoma in a Patient with MEN1. Annals of Surgical Oncology, 2001, 8, 342-346.	1.5	1
112	Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Research, 1999, 27, 1517-1523.	14.5	240
113	Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines. Journal of Biological Chemistry, 1999, 274, 21528-21532.	3.4	407
114	GATA-3 is expressed in association with estrogen receptor in breast cancer. , 1999, 84, 122-128.		164
115	Identification of a Human Akt3 (Protein Kinase B l³) Which Contains the Regulatory Serine Phosphorylation Site. Biochemical and Biophysical Research Communications, 1999, 257, 906-910.	2.1	165
116	Characterization of a gene that is inversely correlated with estrogen receptor expression (ICERE-1) in breast carcinomas. FEBS Journal, 1998, 252, 169-177.	0.2	65
117	Moesin expression is associated with the estrogen receptor–negative breast cancer phenotype. Surgery, 1998, 124, 211-217.	1.9	33
118	hAG-2, the Human Homologue of theXenopus laevisCement Gland Gene XAG-2, Is Coexpressed with Estrogen Receptor in Breast Cancer Cell Lines. Biochemical and Biophysical Research Communications, 1998, 251, 111-116.	2.1	142
119	Ultrasound-Guided Fine-Needle Aspiration Biopsy of Thyroid Masses. Thyroid, 1998, 8, 283-289.	4.5	281
120	Identification of a Gene (GPR30) with Homology to the G-Protein-Coupled Receptor Superfamily Associated with Estrogen Receptor Expression in Breast Cancer. Genomics, 1997, 45, 607-617.	2.9	488
121	Identification of two estrogen receptor transcripts with novel 5′ exons isolated from a MCF7 cDNA library. Journal of Steroid Biochemistry and Molecular Biology, 1997, 62, 143-153.	2.5	46
122	Advances in the diagnosis and management of well-differentiated thyroid cancers. Current Opinion in Oncology, 1996, 8, 37-43.	2.4	7
123	Primary Squamous Cell Carcinoma of the Breast. Southern Medical Journal, 1996, 89, 511-515.	0.7	37
124	Surgical Treatment of Primary Hyperaldosteronism. Annals of Surgery, 1994, 219, 347-352.	4.2	37